ADMA Biologics Investigated for Securities Fraud After Plunge

Investors Notified to Contact BFA Law After Culper Research Alleges Channel Stuffing Scheme

Apr. 3, 2026 at 11:15am

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a stack of polished glass and metal pharmaceutical vials and syringes arranged elegantly on a clean, white seamless background, using dramatic lighting and shadows to conceptually represent the abstract themes of corporate fraud and financial risk.A photorealistic still life of pharmaceutical products highlights the allegations of financial misconduct at ADMA Biologics.NYC Today

Leading securities law firm Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of federal securities laws. The investigation follows a 29% stock plunge after Culper Research published a report alleging ADMA Biologics engaged in a channel stuffing scheme to artificially inflate its 2025 revenue growth.

Why it matters

ADMA Biologics is a biopharmaceutical company focused on manufacturing and developing specialty biologics, with its flagship product being the immune globulin solution ASCENIV. The allegations of channel stuffing, if true, could represent a serious breach of securities laws and undermine investor confidence in the company's financial reporting.

The details

According to the Culper Research report, ADMA Biologics allegedly induced one of its distributors to 'stock excess ASCENIV by offering rebates and extended payment terms' in order to meet revenue expectations in 2025. This allegedly allowed ADMA Biologics to book revenue that 'was never there,' with the company reporting 20% growth when it would have actually experienced a 3% decline without the alleged channel stuffing scheme.

  • On March 24, 2026, Culper Research published its report on ADMA Biologics.
  • On March 23, 2026, ADMA Biologics' stock closed at $13.59 per share.
  • On March 25, 2026, ADMA Biologics' stock closed at $9.63 per share, a 29% decline.

The players

ADMA Biologics, Inc.

An end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics, including its flagship product ASCENIV, a liquid immune globulin solution.

Culper Research

An investigative research firm that published a report alleging ADMA Biologics engaged in a channel stuffing scheme to artificially inflate its 2025 revenue growth.

Bleichmar Fonti & Auld LLP

A leading international law firm representing plaintiffs in securities class actions and shareholder litigation, which has announced an investigation into ADMA Biologics for potential securities law violations.

Got photos? Submit your photos here. ›

What’s next

BFA Law is investigating the allegations and encouraging investors who have purchased ADMA Biologics stock to contact the firm for more information about potential legal options.

The takeaway

The allegations of channel stuffing against ADMA Biologics, if proven true, could represent a significant breach of securities laws and undermine investor confidence in the company's financial reporting, highlighting the importance of robust oversight and transparency in the biopharmaceutical industry.